ES2132076T3 - Pirroles sustituidos. - Google Patents

Pirroles sustituidos.

Info

Publication number
ES2132076T3
ES2132076T3 ES91112829T ES91112829T ES2132076T3 ES 2132076 T3 ES2132076 T3 ES 2132076T3 ES 91112829 T ES91112829 T ES 91112829T ES 91112829 T ES91112829 T ES 91112829T ES 2132076 T3 ES2132076 T3 ES 2132076T3
Authority
ES
Spain
Prior art keywords
elevated
union
sum
pyq
alcali
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91112829T
Other languages
English (en)
Inventor
Peter David Davis
Christopher Huw Hill
Geoffrey Lawton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909017269A external-priority patent/GB9017269D0/en
Priority claimed from GB919109959A external-priority patent/GB9109959D0/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2132076T3 publication Critical patent/ES2132076T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DE LA FORMULA: DONDE R ELEVADO 1 Y R ELEVADO 3, CONJUNTAMENTE, FORMAN UNA UNION Y R (AL CUADRADO) REPRESENTA HIDROGENO O R ELEVADO 1 Y R (AL CUADRADO) , CONJUNTAMENTE, FORMAN UNA UNION Y R ELEVADO 3 REPRESENTA HIDROGENO; R ELEVADO 4, R ELEVADO 5, R ELEVADO 6 Y R ELEVADO 7 CADA UNO INDEPENDIENTEMENTE REPRESENTAN HIDROGENO, ALCALI, HALOALCALI, ALKOXI, NITRO, AMINO, ALKANOILAMINO, AROILAMINO, ALKILTIO O ALKILSULFONILO; R ELEVADO 8 REPRESENTA HIDROGENO, ALCALI O ARALKIL; X REPRESENTA -N(R ELEVADO 9)AL R ELEVADO 9, R ELEVADO 10 Y R ELEVADO 11 CADA UNO REPRESENTA HIDROGENO, ALCALI, ARALKIL O ALKANOIL; M REPRESENTA 0-2 Y N 1-3, CON LA CONDICION DE QUE LA SUMA DE M Y N SEA 1-3; P REPRESENTA 0-4 Y Q 0-4, CON LA CONDICION QUE LA SUMA DE P Y Q SEA 2-4 CUANDO X REPRESENTE -N(R ELEVADO 9)-, QUE LA SUMA DE P Y Q SEA 1-5 CUANDO X REPRESENTE -CHN(R ELEVADO 10, R ELEVADO 11)ELEVADO 1 Y R (AL CUADRADO) CONJUNTAMENTE FORMEN UNA UNION, QUE LA SUMA DE P Y Q SEA 0-4 CUANDO X REPRESENTE -N(R ELEVADO 9)-, R ELEVADO 1 Y R ELEVADO 3 CONJUNTAMENTE REPRESENTEN UNA UNION Y M REPRESENTE 0. ASI COMO SALES FARMACEUTICAMENTE ACEPTABLES DE COMPUESTOS ACIDICOS DE LA FORMULA I CON BASES Y DE COMPUESTOS BASICOS DE LA FORMULA I CON ACIDOS, SON UTILES PARA CONTROLAR Y PREVENIR DESORDENES INFLAMATORIOS, INMUNOLOGICOS, ONCOLOGICOS, BRONCOPULMONARES, DERMATOLOGICOS O CARDIOVASCULARES, O PARA EL TRATAMIENTO DEL ASMA, SIDA O COMPLICACIONES DIABETICAS O PARA LA ESTIMULACION DEL CRECIMIENTO DEL CABELLO. PUEDEN PREPARARSE DE LOS FURANDIONES SUSTITUIDOS CORRESPONDIENTES.
ES91112829T 1990-08-07 1991-07-30 Pirroles sustituidos. Expired - Lifetime ES2132076T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909017269A GB9017269D0 (en) 1990-08-07 1990-08-07 Substituted pyrroles
GB919109959A GB9109959D0 (en) 1991-05-08 1991-05-08 Substituted pyrroles

Publications (1)

Publication Number Publication Date
ES2132076T3 true ES2132076T3 (es) 1999-08-16

Family

ID=26297468

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91112829T Expired - Lifetime ES2132076T3 (es) 1990-08-07 1991-07-30 Pirroles sustituidos.

Country Status (26)

Country Link
EP (1) EP0470490B1 (es)
JP (1) JPH0780880B2 (es)
KR (1) KR100233964B1 (es)
AT (1) ATE179710T1 (es)
AU (1) AU649699B2 (es)
CA (1) CA2046801C (es)
CZ (1) CZ280359B6 (es)
DE (1) DE69131190T2 (es)
DK (1) DK0470490T3 (es)
DZ (1) DZ1521A1 (es)
ES (1) ES2132076T3 (es)
FI (1) FI95909C (es)
GR (1) GR3030677T3 (es)
HU (1) HU210547B (es)
IE (1) IE912787A1 (es)
IL (1) IL99064A (es)
IS (1) IS1682B (es)
MC (1) MC2279A1 (es)
MY (1) MY106400A (es)
NO (1) NO179143C (es)
NZ (1) NZ239216A (es)
PT (1) PT98583B (es)
RO (1) RO112724B1 (es)
RU (1) RU2075474C1 (es)
SK (1) SK279566B6 (es)
UA (1) UA27100A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
AU3761393A (en) * 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
EP0657411B1 (en) * 1993-12-07 1999-06-09 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
PL182124B1 (pl) * 1993-12-07 2001-11-30 Lilly Co Eli Nowe zwiazki oraz srodek farmaceutyczny przeznaczony do leczenia powiklan cukrzycowych lub do leczenia nowotworów PL PL PL PL PL PL PL PL
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6025897A (en) 1993-12-21 2000-02-15 3M Innovative Properties Co. Display with reflective polarizer and randomizing cavity
US6804058B1 (en) 1993-12-21 2004-10-12 3M Innovative Properties Company Electroluminescent light source and display incorporating same
DK0817627T3 (da) * 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5554608A (en) * 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2001503414A (ja) * 1996-10-31 2001-03-13 ハーバー ブランチ オーシャノグラフィック インスティテューション インク． 抗神経性炎症化合物および組成物ならびにその使用法
ATE222104T1 (de) * 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
DE19802708A1 (de) * 1998-01-24 1999-07-29 Hoechst Marion Roussel De Gmbh Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren
DE69920455T2 (de) 1998-07-08 2005-01-20 Harbor Branch Oceanographic Institution Inc., Fort Pierce Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
FR2796274B1 (fr) 1999-07-16 2001-09-21 Oreal Utilisation de l'acide 4,6-dimethoxy-indole 2-carboxylique ou de ses derives pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
JP2007501774A (ja) 2003-08-08 2007-02-01 ノバルティス アクチエンゲゼルシャフト スタウロスポリンを含む組み合わせ
CA2560311A1 (en) * 2004-04-08 2005-10-20 Novartis Ag Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
RU2413511C2 (ru) * 2004-04-08 2011-03-10 Новартис Аг Ингибиторы протеинкиназы с, предназначенные для лечения аутоиммунных заболеваний и отторжения трансплантата
FR2870538B1 (fr) * 2004-05-19 2006-07-14 Servier Lab Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
IL94274A0 (en) * 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
JPH04230686A (ja) 1992-08-19
HU912589D0 (en) 1992-01-28
CA2046801A1 (en) 1992-02-08
GR3030677T3 (en) 1999-11-30
PT98583A (pt) 1992-06-30
DE69131190D1 (de) 1999-06-10
RU2075474C1 (ru) 1997-03-20
IL99064A0 (en) 1992-07-15
NZ239216A (en) 1994-05-26
UA27100A1 (uk) 2000-02-28
CS243591A3 (en) 1992-02-19
KR920004380A (ko) 1992-03-27
IL99064A (en) 1995-08-31
AU649699B2 (en) 1994-06-02
CA2046801C (en) 2002-02-26
ATE179710T1 (de) 1999-05-15
EP0470490A1 (en) 1992-02-12
NO913051D0 (no) 1991-08-06
RO112724B1 (ro) 1997-12-30
PT98583B (pt) 1999-03-31
MC2279A1 (fr) 1993-06-23
HU210547B (en) 1995-05-29
MY106400A (en) 1995-05-30
DZ1521A1 (fr) 2004-09-13
NO179143B (no) 1996-05-06
AU8167291A (en) 1992-02-13
FI913754A0 (fi) 1991-08-07
FI913754L (fi) 1992-02-08
HUT61542A (en) 1993-01-28
DK0470490T3 (da) 1999-11-01
IS3741A7 (is) 1992-02-08
IE912787A1 (en) 1992-02-12
FI95909B (fi) 1995-12-29
NO913051L (no) 1992-02-10
FI95909C (fi) 1996-04-10
KR100233964B1 (ko) 1999-12-15
NO179143C (no) 1996-08-14
CZ280359B6 (cs) 1995-12-13
JPH0780880B2 (ja) 1995-08-30
EP0470490B1 (en) 1999-05-06
SK279566B6 (sk) 1999-01-11
DE69131190T2 (de) 1999-11-04
IS1682B (is) 1998-02-24

Similar Documents

Publication Publication Date Title
IT1206078B (it) Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
NO843968L (no) Fremgangsmaate for fremstilling av 2-amino-5-hydroksy-4-metylpyrimidin-derivater
ES2102367T3 (es) Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
ES533901A0 (es) Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado
NO173998C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
ES2058423T3 (es) Composicion de factor de crecimiento de fibroblastos, resistente a los acidos, para tratar enfermedades ulcerantes del tracto gastrointestinal.
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
PT98583A (pt) Processo para a preparacao de compostos pirrolicos substituidos e de composico-es farmaceuticas que os contem
DK1042315T3 (da) Cyklisk imid-substitueret pyridylalkan, alken og alkin carboxamider nyttige som cytostatiske og immunosuppressive midler
ATE63750T1 (de) Peptid, dessen herstellung und benutzung.
ATE74346T1 (de) Alkensaeurederivate.
NO167734C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte aminderivater.
ES2054738T3 (es) Derivados de acido 3-desmetil-4-fluoromevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su empleo y productos intermedios.
ATE83480T1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
ATE27813T1 (de) N-substituierte 1-(4'-alkylsulfonylphenyl)-2amino-1,3-propanediol-derivate.
DE69531554D1 (de) Verwendung von inosittriphosphat zur herstellung von arzneimitteln
ES2069990T3 (es) Acido acilaminoalquilidenhidroxibisfosfonico util en la terapia de enfermedades osteoarticulares.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
MX9203205A (es) Novedosos acidos dimetilamino-hidroxi-alcan-difosfonicos y sales de los mismos, en procedimiento de produccion y composiciones farmaceuticas relacionadas.
ATE77821T1 (de) Verfahren zur herstellung von penicillansaeurederivaten.
ES2073919T3 (es) Derivados de piperidina 1,3,4-trisubstituidos, su obtencion y empleo.
SE7510365L (sv) Farmaceutisk beredning och forfarande for dess framstellning
SE8801907D0 (sv) Novel pharmacological compounds
NO169127C (no) Analogifremgangsmaate for fremstilling av et terapeutisk aktivt pepti
ES2038702T3 (es) Un procedimiento para preparar derivados triazolopirimidina triciclicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 470490

Country of ref document: ES